Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Kopran Limited (KOPRAN.NS)
Mumbai, IN
Kopran Limited is a fully integrated pharmaceutical entity that manufactures and distributes both active pharmaceutical ingredients (APIs) and finished drug products, serving markets in India and worldwide. Its extensive product portfolio includes a diverse array of dosage formats, such as tablets, capsules, dry powders, suspensions, and injectable solutions. The company's active pharmaceutical ingredients cater to a broad spectrum of therapeutic applications, encompassing macrolides, antibacterials, anticonvulsants, anti-hypertensives, anti-helminthics, antihistamines, anti-acne treatments, anti-infectives, urologicals, anti-thrombotics, antidiabetics, pain management, gastroenterology, and cardiovascular medications. Established in 1958, Kopran Limited maintains its corporate headquarters in Mumbai, India.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -1.94% | +5.26% | +5.57% | +27.51% | +31.95% | +9.02% | -12.38% | +13.06% | -15.79% | +215.38% | -69.80% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | -1 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Drug Manufacturers - General: +6.6%+8.2% ★ Q1'26: +35.8% (vs Q1'25)
-
EPS growth Drug Manufacturers - General: +18.2%-33.3% Q1'26: +94.5% (vs Q1'25)
-
FCF margin FCF growth · Drug Manufacturers - General: +36.0%+7.9% ★ Q1'26: +10.0% (vs Q1'25)
-
EBIT margin Drug Manufacturers - General: +19.4%+8.9% Q1'26: +15.4% (vs Q1'25)
-
ROIC Drug Manufacturers - General: +10.2%+6.7% Q1'26: +15.9% (vs Q1'25)
-
Share dilution Drug Manufacturers - General: +0.0%+0.1% Q1'26: +0.2% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - General: -0.29×1.96× Q1'26: 0.94× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Mar 1996 actual |
Mar 1997 actual |
Mar 2013 actual |
Mar 2014 actual |
Mar 2015 actual |
Mar 2016 actual |
Mar 2017 actual |
Mar 2018 actual |
Mar 2019 actual |
Mar 2020 actual |
Mar 2025 actual |
Mar 2026 1 Rev. Ana. 1 EPS Ana. |
Mar 2027 1 Rev. Ana. 1 EPS Ana. |
Mar 2028 1 Rev. Ana. 1 EPS Ana. |
Mar 2029 1 Rev. Ana. 1 EPS Ana. |
Mar 2030 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
2.66B
est.
|
3.78B
est.
|
2.50B
est: 2.38B (+5.3%)
|
3.03B
est: 3.22B (-5.9%)
|
3.26B
est: 3.56B (-8.6%)
|
2.96B
est: 4.15B (-28.6%)
|
3.10B
est: 3.06B (+1.1%)
|
3.05B
est: 3.18B (-4.1%)
|
3.49B
est: 3.69B (-5.5%)
|
3.50B
est: 4.17B (-16.0%)
|
6.30B
est: 3.56B (+76.7%)
|
4.15B
4.15B – 4.15B
+16.5% YoY
|
3.06B
3.06B – 3.06B
-26.2% YoY
|
3.18B
3.18B – 3.18B
+3.7% YoY
|
3.69B
3.69B – 3.69B
+16.1% YoY
|
4.17B
4.17B – 4.17B
+13.0% YoY
|
| EBITDA |
410.87M
est.
|
-340.53M
est.
|
339.86M
est: -214.75M (+258.3%)
|
379.57M
est: 486.27M (-21.9%)
|
-165.12M
est: 549.47M (-130.1%)
|
258.06M
est: 640.13M (-59.7%)
|
418.74M
est: 472.35M (-11.4%)
|
367.33M
est: 489.96M (-25.0%)
|
469.57M
est: 261.56M (+79.5%)
|
448.17M
est: 642.92M (-30.3%)
|
729.00M
est: 483.25M (+50.9%)
|
562.99M
562.99M – 562.99M
+16.5% YoY
|
415.43M
415.43M – 415.43M
-26.2% YoY
|
430.91M
430.91M – 430.91M
+3.7% YoY
|
500.39M
500.39M – 500.39M
+16.1% YoY
|
565.44M
565.44M – 565.44M
+13.0% YoY
|
| EBIT |
350.34M
est.
|
413.49M
est.
|
215.24M
est: 260.76M (-17.5%)
|
250.36M
est: 414.63M (-39.6%)
|
-319.18M
est: 468.52M (-168.1%)
|
176.88M
est: 545.83M (-67.6%)
|
335.49M
est: 402.77M (-16.7%)
|
282.20M
est: 417.78M (-32.5%)
|
382.18M
est: 221.21M (+72.8%)
|
352.40M
est: 548.20M (-35.7%)
|
573.06M
est: 399.14M (+43.6%)
|
465.00M
465.00M – 465.00M
+16.5% YoY
|
343.12M
343.12M – 343.12M
-26.2% YoY
|
355.91M
355.91M – 355.91M
+3.7% YoY
|
413.29M
413.29M – 413.29M
+16.1% YoY
|
467.02M
467.02M – 467.02M
+13.0% YoY
|
| Net Income |
1.14B
est.
|
81.90M
est.
|
111.19M
est: 51.65M (+115.3%)
|
171.78M
est: 208.63M (-17.7%)
|
-391.24M
est: 269.72M (-245.1%)
|
107.19M
est: 341.61M (-68.6%)
|
199.12M
est: 229.67M (-13.3%)
|
204.86M
est: 289.98M (-29.4%)
|
240.23M
est: 205.59M (+16.8%)
|
210.20M
est: 361.88M (-41.9%)
|
385.52M
est: 269.86M (+42.9%)
|
341.79M
341.79M – 341.79M
+26.7% YoY
|
229.79M
229.79M – 229.79M
-32.8% YoY
|
290.14M
290.14M – 290.14M
+26.3% YoY
|
309.45M
309.45M – 309.45M
+6.7% YoY
|
362.07M
362.07M – 362.07M
+17.0% YoY
|
| SGA |
135.23M
est.
|
1.46B
est.
|
136.39M
est: 918.70M (-85.2%)
|
455.72M
est: 160.05M (+184.7%)
|
—
est: 180.85M (-100.0%)
|
—
est: 210.69M (-100.0%)
|
187.06M
est: 155.47M (+20.3%)
|
202.80M
est: 161.26M (+25.8%)
|
196.71M
est: 323.51M (-39.2%)
|
212.97M
est: 211.60M (+0.6%)
|
605.36M
est: 245.06M (+147.0%)
|
285.49M
285.49M – 285.49M
+16.5% YoY
|
210.67M
210.67M – 210.67M
-26.2% YoY
|
218.52M
218.52M – 218.52M
+3.7% YoY
|
253.75M
253.75M – 253.75M
+16.1% YoY
|
286.74M
286.74M – 286.74M
+13.0% YoY
|
| EPS |
23.64
est.
|
31.18
est.
|
2.85
est: 2.86 (-0.3%)
|
4.40
est: 4.30 (+2.3%)
|
-9.84
est: 5.59 (-276.0%)
|
2.59
est: 7.08 (-63.4%)
|
4.60
est: 4.76 (-3.4%)
|
4.74
est: 6.01 (-21.1%)
|
5.55
est: 6.41 (-13.4%)
|
4.86
est: 7.50 (-35.2%)
|
7.99
est: 5.59 (+42.9%)
|
7.08
7.08 – 7.08
+26.7% YoY
|
4.76
4.76 – 4.76
-32.8% YoY
|
6.01
6.01 – 6.01
+26.3% YoY
|
6.41
6.41 – 6.41
+6.7% YoY
|
7.50
7.50 – 7.50
+17.0% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-22 | B | 3/5 | 1/5 | 3/5 | 4/5 | 2/5 | 2/5 | 4/5 |
| 2026-05-21 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-20 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-19 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-18 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-15 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-14 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-13 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-12 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-11 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-08 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-07 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-06 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-05 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-04 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-30 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-29 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-28 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-27 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-24 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-23 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-22 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-21 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-20 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-17 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-16 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Ajit Jain | Chief Operating Officer | 9M | male |
| Basant Kumar Soni | Chief Financial Officer | — | male |
| Sunil Radheyshyam Sodhani | Company Secretary & Compliance Officer | — | male |
| Surendra Shrikrishna Somani | Chairman & MD | — | male |
| Vandana Somani | Director | — | female |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for KOPRAN.NS
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
